Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle

Sep 23, 2016, 10:03 AM by Michael Croft

Investor's Business Daily | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in.

September 23, 2016 | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in. Investor's Business Daily